Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization
- PMID: 9580385
- DOI: 10.1200/JCO.1998.16.4.1538
Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization
Abstract
Purpose: To evaluate the effectiveness of adding interferon (IFN) alfa-2b to chemotherapy in the induction treatment of low-grade non-Hodgkin's lymphoma (NHL), and to assess the role of maintenance IFN.
Patients and methods: A multicenter, two-phase controlled trial with double randomization was conducted in 155 patients with low-grade NHL. In the first randomization, 78 patients received cyclophosphamide, vincristine, and prednisone (CVP) and IFN, 3 MU/m2 three times a week for 3 months, and 77 patients received CVP alone. Responding patients were randomized to receive IFN for 1 year versus observation.
Results: Of 144 assessable patients, 73 received CVP + IFN and 71 received CVP. Responses were similar: CVP + IFN 79% versus CVP 76% (P = .62). The number of patients who did not complete the treatment was higher in the CVP + IFN group than in the CVP group (18% v 4%; P = .009), although the received dose-intensity of chemotherapy was comparable. Duration of response and progression-free survival (PFS) were significantly higher in the CVP + IFN group than in the CVP group (P = .0004). However, we observed no differences in overall survival (OS) (P = .30), with a median follow-up for the surviving patients of 3 years. Grade 3/4 granulocytopenia was the most frequent toxicity and was similar in both groups (33% v32%). Eighty-three (74%) of the 112 responding patients were randomized to maintenance IFN or observation. The duration of response was similar between 42 patients that received IFN compared with 41 control patients (P = .83), independently of treatment previously administered.
Conclusion: Adding IFN alfa-2b to induction CVP in low-grade NHL did not induce a higher response rate, but it significantly increased the duration of the responses. We found significant differences in PFS that favored the patients who received CVP + IFN, but not in OS. To date, no additional benefit has been seen from the administration of IFN for maintenance.
Similar articles
-
Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.J Clin Oncol. 1998 Jan;16(1):41-7. doi: 10.1200/JCO.1998.16.1.41. J Clin Oncol. 1998. PMID: 9440721 Clinical Trial.
-
Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.J Clin Oncol. 2000 May;18(10):2010-6. doi: 10.1200/JCO.2000.18.10.2010. J Clin Oncol. 2000. PMID: 10811664 Clinical Trial.
-
Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen.J Clin Oncol. 2002 Dec 15;20(24):4649-54. doi: 10.1200/JCO.2002.11.068. J Clin Oncol. 2002. PMID: 12488409 Clinical Trial.
-
Current and future uses of recombinant interferon alpha in the treatment of low-grade non-Hodgkin's lymphoma.Cancer. 1987 Feb 1;59(3 Suppl):658-63. doi: 10.1002/1097-0142(19870201)59:3+<658::aid-cncr2820591315>3.0.co;2-q. Cancer. 1987. PMID: 10822466 Review.
-
Combination chemotherapy in the treatment of follicular low-grade lymphoma.Leuk Lymphoma. 1993;10 Suppl:29-33. doi: 10.3109/10428199309149108. Leuk Lymphoma. 1993. PMID: 8481667 Review.
Cited by
-
Rituximab maintenance in indolent lymphoma: indications and controversies.Curr Oncol Rep. 2007 Sep;9(5):378-83. doi: 10.1007/s11912-007-0051-y. Curr Oncol Rep. 2007. PMID: 17706166 Review.
-
Bayesian hierarchical methods for meta-analysis combining randomized-controlled and single-arm studies.Stat Methods Med Res. 2019 May;28(5):1293-1310. doi: 10.1177/0962280218754928. Epub 2018 Feb 13. Stat Methods Med Res. 2019. PMID: 29433407 Free PMC article.
-
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.Haematologica. 2013 Jul;98(7):1107-14. doi: 10.3324/haematol.2012.082412. Epub 2013 May 3. Haematologica. 2013. PMID: 23645690 Free PMC article. Clinical Trial.
-
Advances and perspectives of dendritic cell-based active immunotherapies in follicular lymphoma.Cancer Immunol Immunother. 2020 Jun;69(6):913-925. doi: 10.1007/s00262-020-02577-w. Epub 2020 Apr 22. Cancer Immunol Immunother. 2020. PMID: 32322910 Free PMC article. Review.
-
A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma.Br J Cancer. 2001 Jul 6;85(1):29-35. doi: 10.1054/bjoc.2001.1822. Br J Cancer. 2001. PMID: 11437398 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials